
    
      The main purposes: to determine the overall survival (OS) of patients who have locally
      advanced inoperable or metastatic HER2-negative gastric and gastroesophageal adenocarcinoma
      treated with first-line EOX (epirubicin + oxaliplatin + capecitabine) or mDCF (docetaxel +
      cisplatin + leucovorin + 5fluorouracil) palliative chemotherapy regimens

      The secondary purposes: to determine safety (as assessed by adverse events according to the
      Common Terminology Criteria for Adverse Events (CTCAE) v4.0) and the progression-free
      survival (PFS)
    
  